



April 30, 2020

Improving Quality of Care: Update of Risks Associated with Use of Fluoroquinolones

Learning Objectives:

- Describe the recent U.S. Food and Drug Administration (FDA) drug safety communications for fluoroquinolones.
- Identify potential adverse effects associated with use of fluoroquinolones.
- Summarize best practices for responsible prescribing of fluoroquinolones.

Key Points:

- Fluoroquinolones are broad-spectrum antibiotics that are FDA-approved to treat various bacterial infections, including infections caused by gram-negative bacilli.
- Over the last decade, the FDA has issued multiple drug safety communications highlighting potential adverse events associated with use of fluoroquinolones.
- Fluoroquinolones should not be prescribed to community-dwelling patients who have other treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated urinary tract infection (UTI), as the risks outweigh the benefits.
- In a study of community-dwelling Medi-Cal fee-for-service beneficiaries, approximately 57% of fluoroquinolone use appeared to be for potentially inappropriate indications, based on FDA recommendations.

Background

Fluoroquinolones, including ciprofloxacin, ofloxacin, gemifloxacin, levofloxacin, and moxifloxacin, are broad-spectrum antibiotics that interfere with the growth of bacteria via inhibition of certain enzymes needed for bacterial replication.¹ Fluoroquinolones are FDA-approved to treat various bacterial infections and can be reliably used to treat infections caused by gram-negative bacilli, including strains of antibiotic resistant bacteria.¹ As shown in Table 1, most fluoroquinolones appear on the Medi-Cal List of Contract Drugs, with some having restrictions to their use without an approved *Treatment Authorization Request* (TAR).

Table 1. Fluoroquinolones on the Medi-Cal List of Contract Drugs

Drug*	Formulation	Restrictions
Ciprofloxacin	Suspension	Treatment of 1) lower respiratory tract infections in persons 50 years of age or older; 2) osteomyelitis; and 3) pulmonary exacerbation of cystic fibrosis.
Ciprofloxacin	Tablets	Treatment of 1) lower respiratory tract infections in persons 50 years of age or older; 2) osteomyelitis; 3) pulmonary exacerbation of cystic fibrosis; 4) UTIs, including pyelonephritis; and 5) prophylaxis of meningococcal disease.
Levofloxacin	Tablets	Maximum quantity per dispensing of ten tablets and a maximum of two dispensings in any 30-day period.
Moxifloxacin	Tablets	Maximum quantity per dispensing of ten tablets and a maximum of two dispensings in any 30-day period.
Ofloxacin	Tablets	Treatment of sexually transmitted diseases.

* Some medications may have additional restrictions on manufacturer codes. For current information, use the online Medi-Cal Formulary search tool available on the [Formulary File](#) page of the Department of Health Care Services (DHCS) website.

Despite the many FDA-approved indications for use, the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (ISDA), the American Thoracic Society (ATS), and other professional organizations all recommend fluoroquinolones not be used as first-line therapy in community settings when other treatment options are available.²⁻⁵ Fluoroquinolones should be initiated only after other antibiotic classes have been tried and failed, or in such cases with a demonstrated drug resistance.²⁻⁵

Over the last decade, the FDA has issued multiple drug safety communications highlighting potential adverse events associated with use of fluoroquinolones, including the following:

- [May 2016](#) – restricting use for certain uncomplicated infections⁶
- [July 2016](#) – increased risk of disabling side effects of the tendons, muscles, joints, nerves, and central nervous system⁷
- [July 2018](#) – increased risk of blood sugar disturbances and certain mental health side effects⁸
- [December 2018](#) – increased risk of ruptures or tears in the aorta blood vessel⁹

The complete list of potential serious side effects provided by the FDA is shown in Table 2.

Table 2. List of Serious Side Effects from Fluoroquinolones⁶⁻¹⁰

System	Side Effect	
Musculoskeletal and Peripheral Nervous System	Tendonitis	Muscle pain
	Tendon rupture	Joint pain
	Numbness or tingling or pricking sensation in arms or legs	Joint swelling
	Muscle weakness	Peripheral neuropathy
Central Nervous System	Anxiety	Hallucinations
	Depression	Insomnia
	Delirium	Paranoia
	Confusion	Seizures
	Memory impairment	Nervousness
	Suicidal thoughts	Disorientation
	Disturbances in attention	
Other Body Systems	Worsening of myasthenia gravis	Serious heart rhythm changes, including QT prolongation
	Aortic dissections	
	Rupture of an aortic aneurysm	Intestinal infection
	Hypoglycemia	Skin rash
	Hyperglycemia	Sunburn

The drug labels also contain limitation-of-use statements to reserve fluoroquinolones for patients who do not have other available treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs, as the risk of these serious side effects generally outweigh the benefits.⁶⁻¹⁰ First-line therapies for these conditions are listed in Table 3.

Table 3. First-Line Alternatives to Fluoroquinolones on the Medi-Cal List of Contract Drugs^{3-5,11-13}

Indication	Drug*	Usual adult dosage (may need adjustment for renal or hepatic impairment)
Acute sinusitis and acute exacerbation of chronic bronchitis due to a bacterial pathogen	Amoxicillin	500 mg PO tid for 5 – 7 days, with a higher dose of amoxicillin (2 g/d) considered for severe disease and those at risk of infection with <i>S pneumoniae</i> with reduced susceptibility to penicillin
	Amoxicillin/clavulanate	875 mg/125 mg PO bid for 5 – 7 days or 500 mg/125 mg PO bid for 5 – 7 days
	Doxycycline	100 mg PO bid for 5 – 7 days
Uncomplicated UTI	Trimethoprim/sulfamethoxazole	160 mg/800 mg PO bid for 3 days
	Nitrofurantoin monohydrate/macrocrystals	100 PO bid for 5 days

- First-line therapies were selected using the IDSA guidelines. Some medications may have additional restrictions on manufacturer codes. For current information, use the online Medi-Cal Formulary search tool available on the [Formulary File](#) Web page of the DHCS website.

For serious bacterial infections, including anthrax, plague, and bacterial pneumonia, and in cases where the infection is severe enough to necessitate hospitalization, the benefits of fluoroquinolones outweigh the risks and it is appropriate for them to remain available as a therapeutic option.²⁻⁵

Fluoroquinolone Use in the Medi-Cal Fee-for-Service Population

A retrospective cohort study was conducted to assess the use of fluoroquinolone antibiotics in the Medi-Cal fee-for-service population using pharmacy and medical claims data. The initial study population included all Medi-Cal fee-for-service beneficiaries with at least one paid claim for a fluoroquinolone between November 1, 2018, and October 31, 2019 (the measurement year).

For each individual beneficiary, the date of service of the fluoroquinolone paid claim was used as the index date and all paid medical claims within seven days prior to the index date were reviewed. In order to focus on beneficiaries living in the community setting, beneficiaries were excluded if one of these paid claims showed the place of service to be a long-term care facility, skilled nursing facility, or inpatient hospital.

In order to determine the appropriateness of fluoroquinolone prescribing, all available medical claims data were reviewed and beneficiaries with any indication of penicillin or other drug allergy that would impact the use of fluoroquinolones as a first-line therapy were excluded from the study population. Any beneficiary with one of the following primary or secondary ICD-10-CM diagnosis codes within the seven-day window of the index date was coded as a potentially inappropriate use of fluoroquinolone:

- Acute bacterial sinusitis – J01.x
- Acute exacerbation of chronic bronchitis due to a bacterial pathogen – J44.1
- Uncomplicated UTI – N30.x or N39.x

Demographic characteristics, including gender, age, race/ethnicity, and geographic region of residence, were reviewed for all beneficiaries in the study population.

Results

A total of 30,144 community-dwelling Medi-Cal fee-for-service beneficiaries had at least one paid claim for a fluoroquinolone between November 1, 2018, and October 31, 2019, and at least one primary or secondary ICD-10-CM diagnosis code within the seven days prior. There were 268 beneficiaries excluded from the study population (1%) as they were identified as having a history of penicillin or other drug allergy that would impact the use of fluoroquinolones as a first-line therapy, leaving a total of 29,876 beneficiaries in the study population.

Approximately two-thirds (n = 17,024; 57%) of fluoroquinolone use during the measurement year appeared to be potentially inappropriate based on the new FDA recommendations, with 2,092 beneficiaries (7%) having a primary or secondary diagnosis of acute bacterial exacerbation of chronic bronchitis, a total of 4,679 beneficiaries (16%) with acute sinusitis, and 10,253 beneficiaries (34%) with an uncomplicated UTI. For reference, uncomplicated urinary tract infection was the most frequent diagnosis given preceding a paid claim for a fluoroquinolone, followed by septicemia.

The demographic characteristics of the study population are shown in Table 4, stratified by appropriate or inappropriate use of fluoroquinolones. Beneficiaries with a paid claim for potentially inappropriate fluoroquinolone use were more likely to be female, 49 years of age and younger, white/Caucasian, non-Hispanic, and live outside of Los Angeles County.

Table 4. Demographic Characteristics of the Medi-Cal Fee-for-Service Study Population (n = 29,876)

	Appropriate Fluoroquinolone Use	Potentially Inappropriate Fluoroquinolone Use
	n (%)	n (%)
Overall population (n = 29,876)	12,852 (43%)	17,024 (57%)
Gender		
• Male (n = 4,481)	3,024 (67%)	1,457 (33%)
• Female (n = 25,395)	9,828 (39%)	15,567 (61%)
Age		
• 49 years of age and younger (n = 22,706)	9,081 (40%)	13,625 (60%)
• 50 years of age and older (n = 7,170)	3,771 (53%)	3,399 (47%)
Race/Ethnicity		
• White/Caucasian, non-Hispanic (n = 3,899)	1,171 (30%)	2,728 (70%)
• All other races/ethnicities (n = 25,977)	11,681 (45%)	14,296 (55%)
California Region of Residence		
• Los Angeles County (n = 12,425)	6,921 (56%)	5,504 (44%)
• All other regions/counties (n = 17,451)	5,931 (34%)	11,520 (66%)

The increased inappropriate use among females may be partially explained by the overall increased incidence of uncomplicated UTIs in this population, as 85% of the population with this indication was female. While the study population had only a relatively small population that was 17 years of age or younger (less than 1,000 beneficiaries), the rate of potential inappropriate use of fluoroquinolones was highest in this age group at 63%. While claims data cannot explain the lower rate of inappropriate use among residents of Los Angeles County, the difference in the rate is significant enough to merit further evaluation in the future. Primarily, it will be important to determine if this lower rate is specific only to fluoroquinolones, or if these data are representative of an effective, comprehensive antimicrobial stewardship program within Los Angeles County that could be studied and replicated statewide.

Conclusion/Discussion

Fluoroquinolone use contributes to the proliferation of antibiotic-resistant bacteria and may result in disabling and potentially permanent side effects. Community-based treatment with fluoroquinolones should be initiated only after other antibiotic classes have been tried and failed, or in such cases with a demonstrated drug-resistance. Limiting the use of fluoroquinolones to those patients where the benefits clearly outweigh the potential risks can lead to improved patient outcomes and a reduction in adverse events.

Clinical Recommendations

General Antimicrobial Stewardship

- Incorporate allergy assessment into routine physical examination and evaluate patients for true penicillin allergy by conducting a history, physical, and (where appropriate) a skin test and challenge dose.
- Prescribe antibiotics carefully and correctly.
 - Avoid treating viral syndromes with antibiotics, even when patients ask for them
 - Obtain microbiology cultures, when possible, before starting antibiotics
 - Be aware of antibiotic-resistance patterns
 - Ensure all orders for antibiotics have the dose, duration, and indications
 - Take an “antibiotic timeout” reassessing antibiotics after 48-72 hours
- Work with pharmacists to ensure appropriate antibiotic use, prevent resistance, and early detection of adverse events.
- Educate patients and their families on appropriate indications for antimicrobials using patient-directed resources and materials, for example those offered by the [Antibiotic Prescribing and Use](#) page of the CDC website.

Use of Fluoroquinolones

- Providers should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs because the risks outweigh the benefits in these patients.
- Pharmacists should discuss the signs and symptoms of adverse events associated with fluoroquinolones with patients, including serious side effects requiring immediate action.
- Providers should discontinue fluoroquinolone treatment immediately if a patient reports serious side effects and switch to a non-fluoroquinolone antibacterial drug to complete the patient's treatment course.
- Avoid fluoroquinolones in patients who have previously experienced serious adverse reactions associated with fluoroquinolones.

References:

1. Oliphant CM and Green GM. Quinolones: a comprehensive review. *Am Fam Physician*. 2002;65(3):455-64. Available at: <https://www.aafp.org/afp/2002/0201/p455.html>. Accessed April 5, 2020.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44Suppl 2:S27-72. Available at: https://academic.oup.com/cid/article/44/Supplement_2/S27/372079. Accessed April 5, 2020.
3. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*. 2011;52:e103-e120. Available at: <https://academic.oup.com/cid/article/52/5/e103/388285>. Accessed April 5, 2020.
4. Chow AW, Benninger MS, Brozek JL, et al. IDSA clinical practice guidelines for acute bacterial rhinosinusitis in children and adults. *Clin Infect Dis*. 2012;54:e72-112. Available at: <https://academic.oup.com/cid/article/54/8/e72/367144>. Accessed April 5, 2020.
5. Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. *Ann Intern Med*. 2016;164(6):425-434. Available at: <https://annals.org/aim/fullarticle/2481815/appropriate-antibiotic-use-acute-respiratory-tract-infection-adults-advice-high>. Accessed April 5, 2020.
6. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain>. Accessed April 5, 2020.
7. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics>. Accessed April 5, 2020.
8. FDA Drug Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side>. Accessed April 5, 2020.
9. FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics>. Accessed April 5, 2020.
10. Kabbani S, Hersh AL, Shapiro DJ, et al. Opportunities to improve fluoroquinolone prescribing in the United States for adult ambulatory care visits. *Clin Infect Dis*. 2018;67(1):134-136. Available at: <https://academic.oup.com/cid/article/67/1/134/4823098>. Access April 5, 2020.
11. Alternatives to Fluoroquinolones. *JAMA*. 2016;316(13):1404-1405.
12. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis executive summary. *Otolaryngol Head Neck Surg*. 2015;152(4):598-609. Available at: <https://journals.sagepub.com/doi/full/10.1177/0194599815574247>. Accessed April 5, 2020.
13. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med*. 2012;366(11):1028-1037.